| DC60032 |
5H-1,2,4-Triazolo[4,3-a]azepine, 3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-6,7,8,9-tetrahydro-
Featured
|
|
|
| DC60033 |
STING INHIBITOR-2
Featured
|
STING inhbiitor, which inhibited the activation of the STING signal pathway and to prevent or treat a STING-mediated disease. |
|
| DC60034 |
STING inhibitor-1
Featured
|
STING inhbiitor, which inhibited the activation of the STING signal pathway and to prevent or treat a STING-mediated disease. |
.jpg)
|
| DC60035 |
MB-07344
Featured
|
MB-07344 is a TH receptor beta agonist and anticholesteremic agent; active metabolite of MB07811. |
|
| DC60036 |
SR-717
Featured
|
SR-717 is an agonist of stimulator of interferon genes STING for treating cancer. SR-717 demonstrates broad interspecies and interallelic specificity. SR-717 functions as a direct cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic that induces the same "closed" conformation of STING. SR-717 displayed antitumor activity; promoted the activation of CD8+ T, natural killer, and dendritic cells in relevant tissues; and facilitated antigen cross-priming. SR-717 also induced the expression of clinically relevant targets, including programmed cell death 1 ligand 1 (PD-L1), in a STING-dependent manner. |
|
| DC60037 |
ManidipineHcl
Featured
|
Manidipine 2Hcl (CV-4093) is a dihydropyridine compound and a calcium channel blocker for Ca2+ current with IC50 of 2.6 nM. IC50 value: 2.6 nMTarget: calcium channelManidipine is described to block T-type Ca2+ channels specifically and is also described to have a high selectivity for the vasculature, presenting negligible cardiodepression as compared to other Ca2+ channel antagonists. Manidipine is also described to not significantly affect norepinephrine levels, suggesting a lack of sympathetic activation with this compound. Manidipine reduces pro-inflammatory cytokines secretion in human endothelial cells and macrophages. Manidipine, unlike other third-generation dihydropyridine derived drugs, blocks T-type calcium channels present in the efferent glomerular arterioles, reducing intraglomerular pressure and microalbuminuria. |
|
| DC60038 |
MFCD07186535
Featured
|
|
|
| DC60039 |
(±)-BAY-1251152
Featured
|
AY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor. BAY1251152 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins. This may cause cell cycle arrest and induce apoptosis, which may lead to a reduction in tumor cell proliferation. |
|
| DC60040 |
glycyl-L-histidyl-L-lysine
Featured
|
|
|
| DC60041 |
Teplinovivint
Featured
|
Teplinovivint is a Wnt pathway inhibitor. |
|
| DC60042 |
YKP-3089
Featured
|
Cenobamate, a sodium channel blocker, enhances GABAergic transmission and has the potential to be a versatile CNS drug. |
|
| DC60043 |
Bupivacaine Hydrochloride
Featured
|
|
|
| DC60044 |
Ethyl 4-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzene Sulfonamide Carbamate
Featured
|
|
|
| DC60045 |
Copper tripeptide
Featured
|
|
.png)
|
| DC60046 |
(S)-Sunvozertinib
Featured
|
(S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against EGFR exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC50=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). |
|
| DC60047 |
SNAP8 Acetate(868844-74-0,free base)
Featured
|
|
.png)
|
| DC60048 |
CPI-0610
Featured
|
CPI-0610 is a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor CPI-0610 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. |
|
| DC60049 |
5-ethyl-4-methyl-N-{4-[(2S)-morpholin-2-yl]phenyl}-1Hpyrazole-3-carboxamide hydrochloride
Featured
|
Ralmitaront, also known as WHO 11130, RO 6889450 and RG7906, is a neuroleptic. |
|
| DC60050 |
N-(1-oxohexadecyl)glycyl-L-histidyl-L-lysine
Featured
|
|
|
| DC60052 |
Prezatide copper acetate
Featured
|
|
|
| DC60053 |
Lobaplatin(D-19466)
Featured
|
Lobaplatin (D-19466) is a diastereometric mixture of platinum(II) complexes containing a 1,2-bis(aminomethyl)cyclobutane stable ligand and lactic acid as the leaving group. Its antitumour activity results from the formation of DNA-drug adducts, mainly as GG and AG intra-strand cross-links. Lobaplatin influences the expression of the c-myc gene, which is involved in oncogenesis, apoptosis and cell proliferation. Lobaplatin has activity in a wide range of preclinical tumour models and appears to overcome tumour resistance to cisplatin and carboplatin in some of these models. In the body, lobaplatin remains largely intact until removed by glomerular filtration. |
|
| DC57000 |
PI4KA inhibitor-1
Featured
|
PI4KA inhibitor-1 is a novel Phosphatidylinositol 4-kinase type IIIα (PI4KA) inhibitor. |
|
| DC57002 |
LIPID C24
Featured
|
C24 is a novel multiprotic ionizable lipid. C24 lipid nanoparticle (LNP) has a multistage protonation behavior resulting in greater endosomal protonation and greater translation compared to the standard reference MC3 LNP. C24 LNP also lower injection site inflammation and higher stability compared to MC3 LNP. |
|
| DC57005 |
1,2-DSPC
Featured
|
1,2-Distearoyl-sn-glycero-3-PC is a phospholipid containing the saturated long-chain (18:0) stearic acid inserted at the sn-1 and sn-2 positions. |
|
| DC57006 |
L319
Featured
|
L319 (LIPID 319) is a novel ionizable, biodegradable lipid for delivery of short interfering RNAs (siRNAs). L319-LPN displays rapid elimination with pKa of 6.38 and also shows well tolerated up to 10 mg/kg. |
|
| DC57008 |
BAMEA-O16B
Featured
|
|
|
| DC57010 |
GLPG2938
Featured
|
GLPG2938 is an antagonists of sphingosine-1-phosphate (S1P) receptor for prophylaxis and/or treatment of diseases including fibrotic, inflammatory, autoimmune, metabolic, cardiovascular, and/or proliferative diseases. GLPG2938 displayed S1P inhibitory |
|
| DC57011 |
DDO-5936
Featured
|
DDO-5936 is a potent PPI inhibitor targeting Hsp90-Cdc37 protein-protein interaction (PPI) as Orally Active Inhibitors for the Treatment of Colorectal Cancer. DDO-5936 disrupted the Hsp90-Cdc37 PPI both in vitro and in vivo via binding to a previously unknown site on Hsp90 involving Glu47, one of the binding determinants for the Hsp90-Cdc37 PPI, leading to selective down-regulation of Hsp90 kinase clients in HCT116 cells. In addition, inhibition of Hsp90-Cdc37 complex formation by DDO-5936 resulted in a remarkable cyclin-dependent kinase 4 decrease and consequent inhibition of cell proliferation through Cdc37-dependent cell cycle arrest. |
|
| DC57012 |
PF-9363
Featured
|
PF-9363 (CTx-648) is a first-in-class potent and high selective KAT6A/KAT6B inhibitor. PF-9363 can be used for the research ofcancer[1][2].
PF-9363 (0~1 μM; 1 day; ZR75-1, T47D and MCF7 cells) down-regulates the expression of H3K23Ac biomarker[1].
PF-9363 |
|
| DC57013 |
Saruparib (AZD5305)
Featured
|
AZD5305 is a potent, selective and oral active PARP inhibitor. AZD5305 is a highly potent inhibitor of PARP1, with significant PARP1-DNA trapping activity, no PARP2-activity, nor binding activity to any other members of the PARP family. AZD5305 has excellent secondary pharmacology and physicochemical properties as well as high oral bioavailability in preclinical species. |
|
